Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel
About
Membership operator: AND
Therapies: 4
Therapies
Atezolizumab (tx:ncit:C106250)
Bevacizumab (tx:ncit:C2039)
Carboplatin (tx:ncit:C1282)
Paclitaxel (tx:ncit:C1411)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel | |
| EMA (1) | EGFR Somatic variants | Non-Small Cell Lung Cancer | Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel | |
| EMA (1) | v::ALK | Non-Small Cell Lung Cancer | Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel |